4.5 Review

The Nucleotide Oligomerization Domain-Like Receptors in Kidney Injury

期刊

KIDNEY DISEASES
卷 2, 期 1, 页码 28-36

出版社

KARGER
DOI: 10.1159/000444736

关键词

Inflammation; Kidney disease; NLRP3; NOD2; Pattern recognition receptors

资金

  1. National 973 Basic Research Program of China [2012CB517700]
  2. National Science Fund for Distinguished Young Scholars [81525005]
  3. National Nature Science Foundation of China [81371317, 81328006, 81470958]
  4. Program for Changjiang Scholars and Innovative Research Team in University (PCSIRT) [IRT13028]
  5. Fundamental Research Funds of Shandong University [2014JC027]

向作者/读者索取更多资源

Background: Inflammation is a hallmark of almost all forms of renal injury and the activation of the innate immune system is of importance in the development of many kidney diseases. Pattern recognition receptors (PRRs) act as sensors of the innate immune system to detect pathogen-or damage-associated molecular patterns, which initiate immune responses to resolve infections and repair damaged tissues. Abnormalities in PRR activation will lead to excessive inflammation. Summary: Nucleotide oligomerization domain (NOD)-like receptors (NLRs) are recently identified intracellular PRRs that are essential to innate immune responses and tissue homeostasis. A better understanding of the function of NLRs will provide unexpected opportunities to develop new therapies for kidney diseases by modulation of the innate immune system. Key Messages: NLRs are constitutively expressed in the kidney and emerging evidence has shown that activation of NLRs plays an important role in the pathogenesis of renal injury. Among NLRs, NOD2 and NLRP3 inflammasome are the best characterized members in the kidney. In this review, we summarize current knowledge about the pathological mechanisms that are related to NOD2 and NLRP3 inflammasome in various kidney diseases by their canonical and non-canonical effects and discuss the opportunities of pharmacological targeting of NLR-mediated signaling pathways at multiple levels for the treatment of renal disease. (C) 2016 S. Karger AG, Basel

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.5
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据